Publications

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.

Chedgy ECp, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J et al..  2018.  Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.. J Pathol.

Choe H, Sboner A, Beltran H, Nanus D, Tagawa ST.  2016.  PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.. Thromb Res. 140 Suppl 1:S192.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH et al..  2012.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.. Mol Cancer Ther. 11(3):775-83.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 4(30):563-577.

Davies AH, Beltran H, Zoubeidi A.  2018.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.. Nat Rev Urol.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, Robinson BD, Troncoso P, Rubin MA.  2014.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.. Am J Surg Pathol. 38(6):756-67.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P et al..  2013.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.. Nat Biotechnol. 31(11):1023-31.

Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JMiguel, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG et al..  2014.  ERG induces taxane resistance in castration-resistant prostate cancer.. Nat Commun. 5:5548.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK et al..  2014.  Organoid cultures derived from patients with advanced prostate cancer.. Cell. 159(1):176-87.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E.  2015.  The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.. Am Soc Clin Oncol Educ Book. :92-103.

Ku SYu, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez ECortes, Wang J et al..  2017.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.. Science. 355(6320):78-83.

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH et al..  2012.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.. J Pathol. 227(3):286-97.

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.  2012.  Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).. BJU Int. 109(7):968-85.

Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y et al..  2017.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.. Eur Urol. 71(1):68-78.

Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O.  2013.  Epigenomic alterations in localized and advanced prostate cancer.. Neoplasia. 15(4):373-83.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L et al..  2014.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.. Cancer Res. 74(4):1272-83.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V et al..  2018.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.. Eur Urol.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia . (1):1-10.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.

O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T et al..  2017.  Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.. Nat Biotechnol. 35(6):577-582.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM et al..  2014.  Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.. Hum Pathol. 45(10):2136-43.